PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 13, 2006New England Journal of Medicine5,798 citationsOpen Access

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

View Full Paper
ASAlan SandlerAlector (United States)RGRobert J. GrayAmerican College of RadiologyMPMichael C. PerryDetroit Medical Center

Key Points

  • The aim is to determine the survival benefits of adding bevacizumab to standard chemotherapy for non-small-cell lung cancer.
  • Randomized trial involving selected patients with non-small-cell lung cancer.
  • Patients received either paclitaxel plus carboplatin alone or with bevacizumab.
  • Clinical trial registered under NCT00021060.
  • Bevacizumab addition resulted in significant improvement in survival.
  • Increased risk of treatment-related deaths was associated with bevacizumab.

Abstract

The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sandler et al. (2006) studied this question.

synapsesocial.com/papers/6985ef813b00292770426f32https://doi.org/10.1056/nejmoa061884
Ask AI
Helpful
Bookmark
Share
View Full Paper